Accelerating Diversity in the Boardroom Through the Strength of the Goodwin Community
GOOD Directors is a first-of-its-kind national program designed to create opportunities for next-generation, BIPOC, LGBTQ+ and women leaders to join Boards of Directors of public companies. GOOD Directors brings together a partnership of leading investment firms and innovative industry players (referred to as ALLIES) and champions of diversity and inclusion already sitting in the boardroom (referred to as CHAMPIONS), along with Goodwin experts in corporate governance and best practices.
Unlike other leadership programs that focus solely on education, GOOD Directors has a board placement component — with the ALLIES committing to use their best efforts to provide participants (referred to as DIRECTOR CANDIDATES) with concrete opportunities for board service following completion of the program.
The first cohort of 20+ DIRECTOR CANDIDATES includes CEOs, COOs, CFOs, and chief business development, strategy, scientific, marketing and product officers from technology, life sciences and other innovative, high growth industries. The DIRECTOR CANDIDATES were selected from a curated list of over 150 executives nominated by ALLIES, CHAMPIONS and Goodwin’s partners. The DIRECTOR CANDIDATES include a substantial majority of BIPOC individuals, a majority of women, and approximately one-third Black professionals.
Goodwin is sponsoring the program as an adjunct to its Annual Directors Forum, which was established in 2007. The inaugural program will launch in the Summer of 2021. GOOD Directors is founded and chaired by the co-leaders of the Annual Directors Forum, Stuart Cable and Lisa Haddad.
What is the GOOD Directors program?
GOOD Directors is an annual leadership program focused on creating opportunities for next-generation, BIPOC, LGBTQ+ and women leaders to join Boards of Directors of public companies. The program is designed to provide 20+ selected individuals without prior public company board experience with the skills and orientation necessary to be effective directors from day one.
Stakeholders today are increasingly aware of, and focused on, the board diversity imperative. As studies and data have consistently shown, diversity in the boardroom brings critical new perspectives and enhances board and company performance. In particular, racio-ethnic, gender and LGBTQ+ diversity can expand a board’s understanding of the needs and viewpoints of its shareholders, customers, partners, employees, regulators, communities and other stakeholders – and also can enhance the decision-making practices of a board. Despite these benefits, qualified individuals from underrepresented groups have not been seated with frequency on boards.
GOOD Directors brings together a partnership of leading investment firms and innovative industry players (referred to as ALLIES) and champions of diversity and inclusion already sitting in the boardroom (referred to as CHAMPIONS), along with Goodwin experts in corporate governance and best practices. Through the strength of the Goodwin community, this program has been designed to more directly address board diversity gaps and accelerate diversity in the boardroom.
Who is sponsoring the program?
Goodwin is sponsoring the program as an adjunct to its Annual Directors Forum, which was established in 2007. Each year, Goodwin invites a select group of public company directors and C-suite executives to participate in an annual forum that is focused on topical issues being discussed in the boardroom. Goodwin has been a pioneer in director education over the years, taking a pedagogical approach focused on interactive sessions that address practical issues affecting directors of public companies. This approach is being extended to GOOD Directors — with classroom learning bolstered by interactive sessions focused on real-life situations..
Goodwin is committed to promoting diversity in our law firm and in the legal profession, and also to creating an inclusive and equitable environment in which each of our employees can excel and thrive. Diversity, equity and inclusion are core to our business and our values, and we regularly partner with our clients with respect to these initiatives. Please click here for further information regarding our commitment to diversity, equity and inclusion.
2021 Alumni Director Candidates
Who will be participating in the program and how will they be selected?
The participants in the program (referred to as DIRECTOR CANDIDATES) are individuals with demonstrated leadership skills and relevant professional, industry and/or financial experience that makes them strong candidates for service on a public company board. Nominations for DIRECTOR CANDIDATES were made by invitation with the goal of assembling a diverse group of individuals who possess a wide range of backgrounds and experience. The DIRECTOR CANDIDATES will include a substantial majority of BIPOC individuals, a majority of women, and approximately one-third Black professionals.
President & Chief Executive Officer, Plexium, Inc.
Percival Barretto-Ko is the President & Chief Executive Officer of Plexium, Inc., a leading next- generation Targeted Protein Degradation (TPD) company. Percival joined Plexium in 2021 with extensive biopharmaceutical experience across various therapeutic areas, functions, and geographies. Through its comprehensive best-in-class TPD platform, powered by a proprietary ultra-high throughput cell-based screening (uHTS) technology, Plexium leads the way in the rational design and discovery of monovalent protein degraders across a wide range of modalities.
Prior to Plexium, Percival was the Chief Business Officer of Astellas Pharma Inc., where he spearheaded the execution of the company’s Corporate Strategic Plan and its efforts to enhance internal and external innovation. Percival’s earlier roles at Astellas included President of Astellas Pharma US, SVP Head of International, and SVP Head of Corporate Strategy, Business Development & Government Affairs. Before joining Astellas, Percival held increasingly senior commercial positions with the Roche Group in the United States and the United Kingdom.
Percival earned a BS in Biological Sciences and Chemistry with Honors from Cornell University and an MBA from Yale University. In addition, Percival served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an MS degree in Management. Percival is a board member of Americares, a health-focused relief and development organization that serves people affected by poverty or disaster with life-changing medicine and health programs.
Chief Operating Officer, FerGene
Ambaw Bellete has served as chief operating officer at FerGene where he has responsibility for the overall commercial organization comprised of sales and marketing, communications and advocacy, analytics, health outcomes research, medical affairs, business development, strategy and patient access.
With more than 30 years of experience working in the biotech, diagnositics and medical device industry, Ambaw has a strong track record of success building and managing multi- disciplinary teams from pre-launch to commercialization. Prior to joining FerGene, Ambaw served as the president of Photocure, a company focused on developing and commercializing pharmaceutical products based on photodynamic technology to treat bladder cancer. He grew revenues by 133% over his last twenty-four months in the organization, which drove an increase in the share price of the company by over 89% in 2019.
Ambaw has also held several global leadership positions with biopharma, biotech and medical device companies, including president of Medical Compression Systems. He started his biopharma career at the Upjohn Company (now Pfizer) and then Sanofi, where he held diverse leadership roles in business development, managed care, marketing and sales positions in specialty, oncology and urology. Ambaw has served on the board of directors for BioNJ and the Chairman of the Board for OncoSTING.
Senior Vice President, ElevateBio
Bhakti B. Bhargava is Senior Vice President at ElevateBio, leading the Finance, Accounting & Strategic Planning function for the company. She joined ElevateBio in 2018 and has played a leading role in building out the firm’s capabilities through significant growth and increasing complexity since then. Bhakti has over 20 years of experience in biotech, consulting and financial services including corporate finance, business development, strategy, and business process re-engineering. Prior to ElevateBio, she was Head of Global Commercial Finance at Alexion Pharmaceuticals, working closely with therapeutic areas to support development, implementation and execution of global franchise strategy and brand planning. Bhakti had previously worked for J.P Morgan in strategy, business management and treasury as part of the Corporate Finance team in Investment Banking and Asset Management. She holds an MBA from Cornell University where she was an Albert Fried, Jr. Fellow and a Bachelor of Science in Computer Engineering from Purdue University.
Chief Product & Experience Officer, Upwork
Sam Bright is a senior executive with over 16 years of experience building and scaling technology teams, businesses, and experiences inorganically and organically. His career reflects a demonstrated track record of building customer-centric experiences, growing multi-billion- dollar P&Ls, executing complex transactions, leading large teams through inflection points, and leveraging his unique perspective as a multicultural millennial consumer paired with his operating experience to “see around corners” on digital strategy.
Currently, Sam is the Chief Product & Experience Officer at Upwork, the world’s largest work marketplace, where he oversees the global product, design, customer experience, community management, trust & safety, talent success, new business initiatives, and business development teams. Previously, he was the Vice President and General Manager of Verticals at eBay where he led a cross-functional team in the development and launch of end-to-end vertical experiences, had P&L responsibility at peak scope for all of eBay’s NA vertical business units (>$30 billion in 2019 Gross Merchandise Volume) and oversaw WHI, a global Software as a Service subsidiary. During prior roles at eBay, he turned around individual vertical business units, executed 70+ partnerships while leading the Strategic Partnerships team, and led four transactions during his stint on the M&A team.
Prior to eBay, Sam advised on over $10 billion of tech M&A deal processes at BofA Merrill Lynch and previously, he rose through the ranks to become the youngest industry analyst at Forrester Research advising Chief Information Officers through tech research and consulting. He began his career leading market research for entrepreneurs at a Northeast Indiana business incubator.
Sam is a member of the Benetech Board of Directors and serves on the Development Committee. He is also a member of the Smithsonian’s National Postal Museum Advisory Council and is a member of the National Association of Corporate Directors (NACD) and credentialed as an NACD Governance Fellow. He has been named to Savoy Magazine's "2020 Most Influential Black Executives in Corporate America," Black Enterprise's 2018 "List of the Most Influential Blacks in Technology,“ and The Network Journal's 2018 "40 Under Forty" class, and is an active supporter of multiple philanthropic causes.
Sam graduated summa cum laude in 3 years with a BA in Management from Taylor University and holds an MBA from Harvard Business School with his elective coursework focused on General Management, Entrepreneurship, and Finance.
Abraham (Abe) Ceesay has served as President for Cerevel since May 2021. Mr. Ceesay has nearly two decades of experience in leading biopharmaceutical companies and commercializing innovative therapeutic products. Mr. Ceesay previously served as the chief executive officer at Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug application enablement for a rare neuroendocrine tumor.
Prior to joining Tiburio, Mr. Ceesay served as chief operating officer at scPharmaceuticals, where he developed and led all operational and commercial aspects of the company. Prior to joining scPharmaceuticals, he served as the head of commercial (sales, marketing, and commercial operations) at Keryx Biopharmaceuticals, vice president of marketing at Ironwood Pharmaceuticals, and in roles of increasing responsibility at Sanofi, formerly Genzyme.
Mr. Ceesay serves on the Board of Directors for Life Science Cares and Camp Harbor View. He holds a bachelor’s degree from Ithaca College, and a Master of Business Administration from Suffolk University’s Sawyer School of Management.
Chief Operating Officer, Third Harmonic Bio
Howard currently serves as COO of Third Harmonic Bio, an Atlas Venture-backed, clinical-stage biotech where he is responsible for corporate & business development, new product planning, and all G&A functions. Howard brings more than 20 years of biopharma industry experience to his current position having held roles across a wide range of functions and therapeutic areas, as well as spanning from early-stage entrepreneurial environments to large pharma / biotech. Before joining Third Harmonic, Howard was VP of Corporate Development at Sophren Therapeutics, a clinical stage neuropsychiatry start-up also founded by Atlas Venture. Prior to Sophren, Howard served as a Principal at Flagship Pioneering where he focused on business development across the firm’s portfolio companies, as well as supporting new company creation in the life sciences. Prior to Flagship, Howard spent five years at Biogen in roles of increasing responsibility across commercial, manufacturing, program leadership, and general management aspects of the business. Howard began his industry career at Novartis in Basel, Switzerland where he held a series of commercial and strategy roles within the neuroscience and ophthalmology disease franchises. Before entering the industry, Howard was a project leader at the Boston Consulting Group where he focused on R&D and portfolio strategy for Fortune 500 biopharma clients.
Howard holds a B.Sc. in chemical engineering from Yale, as well as a Ph.D. in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology.
Venture Partner, Versant Ventures
Peter is a Venture Partner with Versant Ventures. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design Labs Inc. (CDL), which was acquired by Gilead, and Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at MedImmune. He has over 25 years of drug development experience in the fields of oncology, autoimmunity, infectious diseases and inflammation.
Peter holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. At the beginning of his career, Peter did a post-doctoral fellowship at the National Cancer Institute and held roles at Aventis Pasteur and Harvard Medical School.
Partner, General Counsel and Chief Compliance Officer, JMI Equity
Kathy Fields is a general partner at JMI Equity, as well as general counsel and chief compliance officer. JMI Equity is a growth equity firm focused on investing in leading software companies. Founded in 1992, JMI has invested in over 155 businesses in its target markets, successfully completed over 105 exits, and raised more than $6 billion of committed capital. JMI partners with exceptional management teams help build their companies into industry leaders.
Kathy is responsible for deal structuring and execution (including investments and exits), portfolio matters, compliance, and legal and firm administrative functions. She currently serves on the boards of JMI portfolio companies SpaceIQ and Swiftly and is also on the boards of Kognitiv, the American Online Giving Foundation, Inc., and Friends of Downtown San Diego.
Prior to joining JMI in 2013, Kathy was a partner in the corporate, private equity and technology companies groups at Goodwin Procter LLP and prior to that she was a partner in the business practice group at Testa, Hurwitz & Thibeault LLP.
Kathy received a BS from the Indiana University Kelley School of Business and a JD from Stanford Law School.
Senior Vice President and Head of Business Development and Corporate Strategy, Moderna
Said Francis is Senior Vice President, Head of Business Development and Corporate Strategy of Moderna, Inc. He is responsible for leading the vision and execution of the company’s partnering strategy as well as the corporate strategic initiatives, which included in 2020 defining the framework of engagement with governments around Moderna’s COVID vaccine and successfully negotiating numerous critical collaborations and alliances. He joined Moderna in 2013 as a Director of Corporate Development focused on establishing an ecosystem around Moderna’s mRNA platform and expanding the company’s technology portfolio by leading collaborations, licensing transactions, and acquisitions. Prior to joining Moderna, Mr. Francis was a Senior Manager of mergers and acquisitions at Novartis, based in Basel Switzerland, where he drove the successful execution of multiple transactions for various business units (e.g. Novartis Pharma, Sandoz, Novartis Molecular Diagnostics). He started his career at J.P. Morgan Healthcare Investment Banking group in New York City, where he advised pharma and medical device companies on corporate transactions including Merck’s $41Bn+ acquisition of Schering-Plough.
He has deep experience in corporate strategy, growth strategy, business development and corporate governance. Mr. Francis holds an S.B. and M.Eng. from Massachusetts Institute of Technology (MIT) in Electrical Engineering and Computer Science and an MBA from Harvard Business School (HBS).
Chief Financial Officer, IEX Group
Ms. Sara Furber is the CFO of IEX Group, a financial technology company whose mission is to broaden access to high performing technology and financial data. IEX’s flagship business, a U.S. securities exchange, trades more than $12B worth of shares on average daily and ranks as the 8th largest exchange operator globally.
Sara leads IEX’s finance and corporate development efforts, including leading the strategic incubation of new SAAS technology businesses. In 2019, IEX introduced its first such business, called IEX Cloud, a financial data platform which makes it easy for more people to access and use high-quality financial datasets from across the industry.
Prior to joining IEX, Sara held several executive positions at Morgan Stanley, where she was a member of the firm’s Management Committee and the Chief Operating Officer for the Wealth Management division. Previously, she served as Chief Operating Officer for Global Corporate and Investment Banking at Bank of America Merrill Lynch and ran investor relations for Merrill Lynch during the credit crisis.
Sara started her career in investment banking and has a degree in Mechanical Engineering from Duke University.
Currently she is a member of the Board of Directors for Ronald McDonald House New York, the Board of Visitors for Duke University's Pratt School of Engineering, the Advisory Board for Rewriting the Code, The Board of Directors for Tradewind Markets and the Board of Directors for IEX Group.
Vice President and Head of Global Digital Go-to-Market, Thomson Reuters
Sadaf Kazmi is a seasoned product management and technology executive with deep expertise in ecommerce, strategy, transformation, and operations.
Currently Sadaf is the head of Product Strategy, Analytics, and Operations at Audible, an Amazon subsidiary. In this role, she focuses on identifying and operationalizing customer-obsessed growth opportunities for the company. Prior to joining Audible in 2021, Sadaf held digital leadership positions at Thomson Reuters including Vice President and head of Global Digital Commerce & Online Operations. In this position, she led a global team responsible for the transformation, customer experience, and operations of the company’s ecommerce platforms, marketing sites, online operations, and marketing technology stack.
Before joining Thomson Reuters, Sadaf held several senior positions at Staples, including Vice President of B2B Ecommerce, where she was responsible for StaplesAdvantage.com, a multi-billion dollar ecommerce platform and the largest online business of Staples, Inc.. Earlier in her career, Sadaf spent many years as a technology and digital strategy consultant.
Sadaf holds an MBA from the Wharton School, a JD from the University of Pennsylvania Law School, and a BSE in Engineering from the University of Pennsylvania School of Engineering and Applied Sciences. She serves on the Trustees Council of Penn Women and as a mentor for the MIT Venture Mentoring Service. Sadaf resides in Brookline, MA with her husband and two daughters.
Global Head of Partnership Strategy and Operations, Twitter
Alex is the Director of Client Solutions at Twitter. In this role, she leads a commercial team focused on Retail and Travel companies. She and her team advise clients on how best to utilize the platform to reach their target consumer and achieve their business objectives. Previously, Alex was the Global Head of Partnership Strategy and Operations at Twitter. In that role she was responsible for the development of the Global Content Partnership strategy that both enabled sustainable revenue growth and enhancement of the user experience on the platform. Alex serves as an executive advisor to Twitter Women, a business resource group focused on building community for women at Twitter.
Prior to Twitter, Alex served as Chief of Staff to the Chief Digital Officer at Under Armour (UA) with a focus on Corporate and Digital Strategy. Over the course of nine years, Alex served in a variety of roles that shaped how UA approached their digital strategy. This included the $700M+ dollar acquisition and integration of three tech companies – MapMyFitness, MyFitnessPal, and Endomondo – that together resulted in a digital fitness community of more than 120 million registered users, the largest at that time. Post acquisition, Alex was responsible for helping prioritize and consolidate product roadmaps, driving resource efficiencies in the disparate engineering organizations, as well as supporting monetization of global users.
Additionally, Alex serves on the board of ConnectED, a national nonprofit focused on making learning real, rigorous, and hands-on to ensure preparation for both college and career. She also serves as an advisor to the Center for Conscientious Leadership, an organization focused on developing the next generation of leaders.
Alex is a nationally sought after speaker and thought-leader. She was a featured presenter at various conferences and events including AdWeek, Association of National Advertisers (ANA), Princeton University, Business Today, Black in Tech among others and has led multiple celebrity panel discussions as part of industry promotional tours.
Alex is a graduate of Princeton University and proud native of Washington, DC. She currently resides in Oakland, California.
Global Head of the AI Innovation Center, Novartis
Dr. Iya Khalil is the Global Head of the AI Innovation Center at Novartis leading the development and application of innovative AI algorithms and platforms across the pharma pipeline. She is a serial entrepreneur and AI pioneer with 20+ years of professional experience in AI and “Big Data” for Healthcare and Life Sciences. She co-Founded two AI companies and is the co-inventor of the proprietary machine learning engine that underpins both entities. As an entrepreneur, she drove the success of her ventures by establishing and running key collaborations with pharmaceutical companies, foundations, payers, providers and government agencies. She has extensive experience in developing AI applications across the continuum of Pharmaceutical R&D to healthcare, including drug discovery, drug development, clinical trials, and real-world evidence and treatment algorithms for patients. Named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry for abilities to build bridges across the life science and healthcare industries, and for bringing people together to harness the power of computational modeling to change the lives of patients. She serves as an advisor to the Bill and Melinda Gates Foundation and is on the boards of the CropIn and the Scientific Advisory Board of Biocentury Innovations; the Board of Overseers at the Museum of Science, and the Advisory Board of the Convergence Forum. Appointed to the Massachusetts Center for Health Information and Analysis (CHIA) Oversight Council by Governor Charlie Baker. Dr. Khalil is a frequent speaker at industry events and conferences and has appeared in several industry journals; published several peer reviewed articles in the field; and recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine. She has been named to Inc magazine’s list of top female founders of 2018, as well as more recently in the Forbes 2019 top women-led startups “crushing tech.”
President and CEO, Steele Compliance Solutions
Eric Lochner is MeetingPlay + Aventri’s Chief Executive Officer and serves as a member of the board of directors. Prior to MPAV, Eric served as president and CEO at Steele Compliance Solutions which was acquired by Diligent Corporation in 2021. He has over 25 years of senior management experience leading high-growth cloud-based software and technology enabled services companies. Prior to Steele Compliance Solutions, he served as president and CEO of Achievers, where he used his wealth of knowledge and experience in the technology and human capital management sectors to ensure Achievers’ solutions deliver long-term value to customers. Achievers was acquired by Blackhawk Networks in 2015. Prior to Achievers, Eric spent nine years at Kenexa, a human capital management company that sold to IBM in 2012. During his time at Kenexa, he served in a wide variety of roles including: President of the Talent Management Software division, Chief Marketing Officer and Managing Director of EMEA. His extensive experience in Software-as-a-Service and Professional Services also includes time at CareerBuilder.com, where he led the company’s marketing efforts. He earned his Master of Business Administration degree from Northwestern University’s Kellogg Graduate School of Management and his Bachelor of Arts degree from John Carroll University. Eric also serves on the board of directors for vCheck Global.
Chief Marketing Officer, Flywire
As Chief Marketing Officer, Allison leads Flywire’s global marketing strategy. Her focus is on amplifying the company’s brand, and scaling its performance in marketing, global communications and sales enablement efforts. She has over 15 years of marketing experience, including seven years at Rapid7. There, she focused on building and optimizing the company’s growth by building and scaling demand generation, technology and analytics, and building strong teams. Previously, she worked at Forrester in several digital and field-based roles that included establishing the research firm’s international corporate marketing function in Europe and driving its online localization strategy. Allison holds a Master of Arts in Integrated Marketing from Emerson College, and a Bachelor of Arts in Communications from the University of Massachusetts, Amherst.
Chief Financial Officer, Squarespace
Marcela Martin is Squarespace’s Chief Financial Officer, leading the company’s financial and corporate development functions. Marcela has more than 25 years of financial and operations experience at global tech and media companies, most recently as SVP and CFO of Booking.com. Previously, she spent three years at National Geographic Partners as Executive Vice President, CFO & Chief Administrative Officer and 18 years in numerous leadership positions, including EVP and CFO, at Fox International Channels. Originally from Argentina, Marcela graduated from the University of Morón with expertise in accounting and received a M.B.A. from the University of Liverpool.
Chief Executive Officer, PetPeople
Carrie McDermott as been with PetPeople since 2018. Prior to joining PetPeople, Carrie, was President of Sally Beauty, where she was focused on leading the business transformation. Prior to Sally, she served nine years in roles of increasing responsibility with DSW Inc., where most recently she served as Chief Operating Officer. In this role, Carrie successfully led the Company’s operations, marketing, and customer experience.
Prior to DSW, Carrie served as DSW’s Executive Vice President of Sales and Operations, where she was responsible for driving the Company’s omni-channel initiative, launching ship-from-store, and successfully opening 200 stores. Prior to DSW, Carrie had leadership roles with other retailers, including Cooper’s, Inc., (a family-owned specialty retail business), The Gap, Inc., and Barnes & Noble, Inc. Carrie lives in Columbus, Ohio with her husband and three children and is the pet parent to two rescue dogs, a mini-Australian Shepard, and a Australian Cattle Dog mix.
CEO and Co-Founder, Observable
Melody Meckfessel is the CEO and co-founder of Observable, the destination for data visualization. Observable empowers people to explore, analyze and visualize data on the web, together. Melody is a hands-on leader with decades in engineering at both startups and enterprises. Prior to Observable, she was a VP of Engineering at Google.
Chief Scientific Officer, Faze Medicines
Dr. Rachel Meyers currently serves as the chief scientific officer at Faze Medicines, a company focused on the regulation of biomolecular condensates to treat disease. She was most recently an entrepreneur-in-residence at Third Rock Ventures (TRV), where she helped drive the creation of Faze Medicines. Prior to joining TRV, Rachel was a consultant, advising a number of biotech companies and venture capital firms and currently serves on a number of Scientific Advisory Boards.& She joined TRV from Alnylam Pharmaceuticals (2003 – 2017), where she was most recently senior vice president of research and RNAi lead development. In this capacity, she played a key role in advancing RNAi therapeutic programs from early discovery through clinical development, and her team was responsible for program leadership for most of the company’s preclinical and clinical stage programs. Rachel also had overall responsibility for the chemistry and platform technology efforts that are the underpinnings of the company’s pipeline. She was the project lead for the company’s RSV program, where she was responsible for advancing ALN-RSV01 from inception, through preclinical development and into the clinic. In 2007, Rachel was honored by Mass High Tech as one of 10 Women to Watch and by R&D Directions as one of its Top 20 Scientists. Before joining Alnylam in 2003, Rachel was a senior scientist at Millennium Pharmaceuticals (1999 – 2003) where she led a unit of the company’s target discovery and validation efforts involving bioinformatics and molecular and cell biology. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her Ph.D. from MIT in the field of in vitro transcription.
General Counsel and Chief Compliance Officer, Battery Ventures
Lizette Pérez-Deisboeck has been the General Counsel and Chief Compliance Officer of Battery Ventures, a global, technology-focused investment firm, since 2009. Lizette joined Battery from Goodwin Procter, where she was a partner. She has over 25 years of legal experience counseling entrepreneurs, public companies, and private clients on a variety of matters, including formation, governance, financings, strategic alliances and mergers and acquisitions in the United States and abroad. Prior to Goodwin, Lizette was Vice President of Legal Affairs and Operations, at Idealab, a creator and operator of technology companies. Preceding her work at Idealab, she served as General Counsel at JuniorNet Corporation, a children’s online service. Lizette served as law clerk to the Honorable Michael A. Telesca of the United District Court of the Western District of New York. She is a member of the California and Massachusetts Bar Associations. Lizette earned her JD from Boston University School of Law and received a Bachelor of Arts from the University of Rochester. She serves as a member of the Board of Trustees of the University of Rochester, a private research university, and the Board of Advisors of GBH, the leading multiplatform creator for public media in America. She also serves as a member of the audit committee of the GBH Board of Trustees.
Vice President of Humio Business Unit, CrowdStrike
Geeta Schmidt is the Vice President of the Humio Business Unit and is responsible for the team building out the product, development and market opportunities for Humio at CrowdStrike. Humio was acquired in 2021 by CrowdStrike and prior to this Geeta was a start-up Co-Founder and CEO at Humio. Geeta has over 20 years of software industry experience and is passionate about creating great products for software developers. In her previous role at Trifork, Geeta was the team lead for the expansion and production of GOTO Conference Series which grew from one conference in Denmark to an international series with activities in 6 cities worldwide. Geeta managed strategic partnerships to launch QCon SF and QCon London conferences, Scala Days, FlowCon events. Prior to Trifork, Geeta held product and partner marketing roles in the financial services, market development and new product introduction teams at Sun Microsystems (acquired by Oracle). Geeta is an ex-pat from Seattle living in Aarhus, Denmark.
Former Global Head of Business Marketing
David Scott has over 20 years of marketing experience and has served as a senior marketing executive for top software companies such as Twitter, Honeywell, Peoplesoft, Oracle, and AT&T. Mr. Scott is widely considered an expert in performance marketing, integrated marketing, and growth marketing. He also has deep experience in branding, public relations, social media, advertising, and digital media.
Most recently, David Scott was the Global Head of Business Marketing for Twitter where he oversees all non-consumer marketing. Mr. Scott brings a mixture of big and small business experiences. He has held executive roles at AT&T, Peoplesoft, Honeywell, and GE. In addition, he was the Chief Marketing Officer of several VC backed startups, all successfully exited. He has been an entrepreneur as well. Mr. Scott started and sold NextPlanetOver (e-commerce company), Marketfish (marketing automation platform), and Laughly (streaming comedy service).
David Scott is passionate about growth and performance marketing. He’s the author of two bestsellers on the topic of growth marketing. The New Rules of Lead Generation: Proven Strategies to Maximize Marketing ROI and The Essentials of Small Business Marketing are both published by Harper Collins. He also teaches growth marketing at Haas Business School and speaks at marketing conferences around the world.
Mr. Scott has received a number of industry awards including “CMO of the Year” and "Marketer of the Year." David Scott earned dual bachelor degrees in computer science and political philosophy from The College of William and Mary and earned his MBA at the Wharton School at the University of Pennsylvania where he graduated with distinction.
Dave currently sits on the alumni board of his alma mater and was previously on the board of Goodwill, the Boys and Girls Club of Seattle, and the Data Marketing Association. In 2007, he was named to the Puget Sound Business Journal’s “40 Under 40″ award.
Chief Executive Officer and Co-Founder, Finix
Richie Serna is the Chief Executive Officer and co-founder of Finix. Finix is a payments infrastructure provider for software companies that want to transform their business model by embedding payments into their product to create a better user experience for customers while adding an entirely new revenue stream. Prior to Finix, Richie was an early employee and engineer at Balanced, the first developer-friendly payments API for online marketplaces. He was also a consultant at Booz & Company and earned his B.A. in government from Harvard University.
Director of Product Management, YouTube
Erin Teague is a Director of Product Management at YouTube. In this role, she is the global product lead for several product verticals including Sports, Racial Justice, and new subscriptions businesses. Prior to this role, Erin led YouTube’s Virtual and Augmented Reality product team where she was responsible for immersive video and created the YouTube VR app which is rated #1 across multiple platforms. Before YouTube, Erin was the Director of Product for Yahoo’s Fantasy Sports and Product Manager at Twitter. She began her career as a software engineer at Morgan Stanley, where she designed algorithms embedded in electronic trading applications in the firm’s Algorithmic Trading Technology group.
Erin is the recipient of the 2019 BET Her Tech Maven Award and has been recognized as one of the “100 Most Influential Women in Silicon Valley” by Silicon Valley Business Journal, “The Next Generation of Tech Stars” by Refinery29, “40 Under 40 in Silicon Valley”. She has also been named one of Glamour Magazine’s “35 Women Under 35 Who Are Changing the Tech Industry” and one of Business Insider's "Silicon Valley 100."
Originally from Detroit, Michigan, Erin holds a M.B.A. from Harvard Business School, where she was a Morgan Stanley Fellow, and a B.S.E. in Computer Engineering from the University of Michigan, where she graduated with honors as an Intel Scholar.
Who are the Allies and what is their role?
The program is being conducted in partnership with select investment firms and innovative industry players that are similarly committed to advancing diversity in the boardroom. In addition to providing nominations for DIRECTOR CANDIDATES, these ALLIES are committing to use their best efforts to provide DIRECTOR CANDIDATES with concrete opportunities for board service following completion of the program.
Accel works with startups in seed, early and growth-stage investments. For more information, please visit https://accel.com/.
Acrew Capital is a leading venture firm that engages in a long-term partnership with world-class teams uniquely suited to solving big, challenging problems. We believe that depth of domain knowledge and diversity of perspective drive success in venture. Through both Acrew’s early and growth stage funds, we support our portfolio companies in diversifying both their ownership and management teams. For more information, please visit https://acrewcapital.com/.
Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For more information, please visit https://ampersandcapital.com/.
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit http://www.atlasventure.com/.
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures. For more information, please visit https://www.battery.com/.
Bessemer Venture Partners helps entrepreneurs lay strong foundations to build and forge long-standing companies. With more than 135 IPOs and 200 portfolio companies in the enterprise, consumer and healthcare spaces, Bessemer supports founders and CEOs from their early days through every stage of growth.
Bessemer’s global portfolio includes Pinterest, Shopify, Twilio, Yelp, LinkedIn, PagerDuty, DocuSign, Wix, Fiverr and Toast and has $19 billion of capital under management. Bessemer has teams of investors and partners located in Tel Aviv, Silicon Valley, San Francisco, New York, London, Boston, Beijing and Bangalore.
Born from innovations in steel more than a century ago, Bessemer’s storied history has afforded its partners the opportunity to celebrate and scrutinize its best investment decisions (see Memos at bvp.com/memos) and also learn from its mistakes (see Anti-Portfolio at bvp.com/anti-portfolio).
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives. More information is provided at https://www.blackstone.com/our-businesses/life-sciences/.
Bregal Sagemount is a leading growth-focused private capital firm with more than $5.5 billion of capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 60 companies in a variety of sectors including software, financial technology & specialty finance, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York, Dallas, and Redwood City.
For more information, visit the Sagemount website: www.sagemount.com.
Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas. While we love speedy success, we’re acutely aware that greatness comes in many forms and at different times. That why we’re not afraid to break the mold to bring something spectacular to life.
Based in Boston and New York, Charlesbank Capital Partners is a middle-market private investment firm with more than $15 billion of capital raised since inception. Charlesbank focuses on management-led buyouts and growth capital financings, as well as opportunistic credit and technology investments. The firm seeks to build companies with sustainable competitive advantage and excellent prospects for growth. For more information, please visit https://www.charlesbank.com/.
Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $80 billion in aggregate value. To date, Flagship has deployed over $2.3 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. For more information, please visit flagshippioneering.com.
F-Prime Capital creates and invests in healthcare and technology companies that impact lives all over the world. For more information, please visit https://fprimecapital.com/.
General Catalyst is a venture capital firm that invests in powerful, positive change that endures — for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Deliveroo, Guild, Gusto, Hubspot, Illumio, Lemonade, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker. For more information, please visit https://www.generalcatalyst.com/.
We partner early with consumer and enterprise software entrepreneurs. Our mission is to help realize rare potential. For more information, please visit https://greylock.com/.
Index Ventures is an international venture capital firm, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security. For more information, please visit https://www.indexventures.com/.
JMI Equity is a growth equity firm focused on investing in leading software companies. Founded in 1992, JMI has invested in over 170 businesses in its target markets, successfully completed over 110 exits, and raised more than $6 billion of committed capital. JMI partners with exceptional management teams to help build their companies into industry leaders. For more information, visit www.jmi.com.
Marlin Equity Partners is a global investment firm with over $7.5 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthen a company’s outlook and enhance value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 180 acquisitions. The firm is headquartered in Los Angeles, California with an additional office in London. For more information, please visit https://www.marlinequity.com/.
MPM Capital is a biotechnology investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals, entrepreneurs, and advisors, MPM strives to power novel medical breakthroughs that transform patients' lives. For more information, please visit https://www.mpmcapital.com/.
RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community.
Sequoia helps daring founders build legendary companies from idea to IPO and beyond. We aim to be the first true believers in tomorrow’s most valuable and enduring businesses. We partner with a few outliers each year and go all-in, providing them with the hands-on help required at every stage of the company building journey. Our expertise comes from nearly 50 years of working with legendary founders like Steve Jobs, Larry Page, Jan Koum, Adi Tatarko, Brian Chesky, Anne Wojcicki, Eric Yuan, Julia Hartz, and Patrick Collison. In aggregate, Sequoia-backed companies account for more than 25% of NASDAQ's total value. Since our inception, the vast majority of the money we invest has been on behalf of nonprofits and schools like the Ford Foundation, Mayo Clinic and MIT, which means most of the returns we generate benefit these great causes. https://www.sequoiacap.com/
Spark Capital is a leading mid-market investment bank that provides focused solutions to its clients. Started by a group of passionate and well-networked finance professionals, Spark is today recognized as a leading go-to investment bank in the South, specifically among mid-market corporates. For more information, please visit https://www.sparkcapital.com/.
TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $33.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. For more information, please visit https://www.ta.com/.
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients. By starting with big ideas and fostering collaboration among people with expertise in science, medicine, business and strategy, we aim to discover, launch, and build innovative companies that can transform the lives of patients. Our mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. For more information, please visit https://www.thirdrockventures.com/.
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $4.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit https://www.versantventures.com/.
Who are the Champions and what is their role?
The program is being conducted in partnership with select investment firms and innovative industry players that are similarly committed to advancing diversity in the boardroom. In addition to providing nominations for DIRECTOR CANDIDATES, these ALLIES are committing to use their best efforts to provide DIRECTOR CANDIDATES with concrete opportunities for board service following completion of the program.
Executive Vice President, Head of Development and CMO, Sana Biotechnology; Board Member — Calithera
Sunil Agarwal, MD, is Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology.
He was most recently President of Research and Development at Juno Therapeutics. Previously, he was a Partner in Sofinnova, a Menlo Park, California-based biotech-focused investment firm. He is also a former Executive Vice President and Chief Medical Officer for Ultragenyx Pharmaceutical, where he managed the company’s clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology, and toxicology functions.
Sunil served in various leadership roles at Genentech for more than a decade, including Senior Vice President and Global Head of Clinical Development for ophthalmology, metabolism, neurosciences, immunology, and infectious diseases. He led the approval of multiple therapies at Genentech including RITUXAN®, ACTEMRA®, LUCENTIS® and XOLAIR®. Earlier in his career, Sunil was at MedImmune and Guilford Pharmaceuticals, where he served in both development and medical affairs and led the formation of Guilford’s Medical Affairs Organization.
He served on the board of Myokardia which was sold to BMS in 2020 for 13 billion and is currently on the board of Calithera.
Sunil completed his residency at Children’s National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He obtained his B.S. in neurobiology from Cornell University and earned his MD from Tufts University School of Medicine.
Board Member — Verizon, Nordstrom, Roper Technologies, and Okta
Ms. Archambeau is an experienced CEO and Board Director with a track record of accomplishments building brands, high performance teams, and organizations. Ms. Archambeau currently serves on the boards of Verizon [NYSE:VZ], Nordstrom [NYSE: JWN], Roper Technologies [NYSE: ROP], and Okta [NASDAQ: OKTA]. She is also a strategic advisor to Forbes Ignite and to the President of Arizona State University, and serves on the boards of two national nonprofits, Catalyst and Braven.
She is the former CEO of MetricStream, a Silicon Valley-based, governance, risk, and compliance software company that enables corporations to improve their business operations through better risk management across the enterprise. Ms. Archambeau built the company into a global market leader with over 1200 employees serving customers around the world. Under her leadership MetricStream was recognized for growth and innovation over the years and was named in the top 10 of the “Deloitte Technology Fast 50” and named a global leader in GRC by leading independent analyst firms for 9 consecutive years.
Ms. Archambeau has over 30 years of experience in technology leading organizations focused on business to business as well as business to consumer. She is a recognized expert in marketing and co-authored, "Marketing That Works: How Entrepreneurial Marketing Can Add Sustainable Profits to Any Sized Company." She has held EVP of Sales and Chief Marketing Officer roles for two public companies and as President of Blockbuster.com, launched the entertainment retailer’s first online presence.
She was named the second most influential African American in IT by Business Insider. She was ranked one of the “100 Most Influential Business Leaders in America” by Newsmax and that same year received the NCWIT Symons Innovator Award from The National Center for Women & Information Technology (NCWIT).
She is the author of Unapologetically Ambitious: Take Risks, Break Barriers and Create Success on Your Own Terms (Published by HBG Grand Central 10/2020). A book that helps professionals achieve their aspirations and create the life they want.
Shellye is also a sought-after speaker on governance, risk and compliance as well as marketing and entrepreneurship. She has guest lectured at Stanford’s Graduate School of Business and The Wharton School of Business. She is a Forbes contributor and has been featured or referenced in major publications such as The Wall Street Journal, The New York Times, and The Financial Times.
In her spare time Shellye enjoys exercising, the performing arts, entertaining and cooking.
Board Member — PBF Energy
Wayne Budd is senior counsel in Goodwin's Litigation Department, where he specializes in advising clients on business and commercial litigation matters. Mr. Budd had previously been a partner at Goodwin from 1993 to 1996.
Mr. Budd has represented numerous entities in significant litigation and business related matters, including Digital (Hewlett-Packard), Blue Cross/Blue Shield, Filene's Basement, the Massachusetts State Lottery Commission, Bank Boston, and the State of Rhode Island as among other corporate and institutional clients.
In May 2005, Mr. Budd was appointed to serve on the Executive Committee of the National Emerging Infectious Diseases Laboratories (NEIDL). He was a director of the McKesson Corporation where he served as the Presiding Director and subsequently served as Chair of the Committee on Governance. He currently serves as a director of PBF Energy, a NYSE listed Company, and chairs the Nominating and Governance Committee of the Board. Mr. Budd has served on the Board of the American Automobile Association (AAA) of Southern New England, and has served as Chairman of the National Board of AAA. He is also a Trustee Emeritus of Wheaton College and currently a Trustee at New England Law/Boston. Mr. Budd was formerly a member of the Senior Advisory Committee for the Institute of Politics at Harvard University, and a former Vice Chairman of the Greater Boston Chamber of Commerce. He was also a director of the National Association of Former U.S. Attorneys.
Prior to rejoining Goodwin in 2004, Mr. Budd served as a member of the board of directors and as Senior Executive Vice President and General Counsel at John Hancock Financial Services Inc., where he was responsible for directing all of the company’s legal activities as well as overseeing the compliance, human resources, governmental affairs and community relations functions for the Company. Before joining Hancock, Mr. Budd was Group President-New England of the Bell Atlantic Corporation (now Verizon Communications), where he was responsible for the policy, regulatory, and legislative functions for the New England states served by the Company.
Before entering the private sector, Mr. Budd had been Associate Attorney General of the United States, appointed to the position by President George H.W. Bush in 1992. He oversaw the Civil Rights, Environmental, Tax, Civil and Anti-Trust divisions at the Department of Justice, as well as the Bureau of Prisons. From 1989 to 1992, Mr. Budd was the United States Attorney for the District of Massachusetts, serving as the state’s chief federal prosecutor and representing the federal government in all matters involving civil litigation. During this time, he was recognized for his efforts in combating drugs, street crime and gang violence. Mr. Budd has also served as a member of the U.S. Sentencing Commission, appointed to that position by President Bill Clinton.
President and CEO, Rubius Therapeutics; Board Member — Fusion Pharmaceuticals, Repertoire Immune Medicines, Rubius Therapeutics, and Synthekine
Pablo Cagnoni is president and chief executive officer of Rubius Therapeutics. Over the course of Pablo’s career as an oncologist and pharmaceutical executive, he has been committed to advancing the development of breakthrough treatments for people with cancer and other diseases. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor®, Kyprolis® and Tarceva®.
Before joining Rubius in 2018, Pablo served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion. Prior to Tizona, he served as President of Onyx Pharmaceuticals (acquired by Amgen), where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).
Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Pablo earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
He is a member of the Board of Directors for Fusion Pharmaceuticals, Repertoire Immune Medicines and Synthekine. He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics and was Executive Chairman of Blade Therapeutics.
Lead Independent Director — Citrix Systems; Board Member — Equinix, CIBC, and Procore
Nanci Caldwell is a highly experienced executive in the IT industry with a proven track record in Sales, Marketing, and General Management.
Nanci was Executive Vice President and CMO for PeopleSoft from 2001 until it was acquired by Oracle in 2004. Prior to joining PeopleSoft, Nanci spent 19 years at HP where she held a number of senior management positions in sales, marketing, and general management.
Nanci currently serves as a Corporate Director at the following corporations: Citrix Systems, Inc. and serves as Lead Independent Director, Chair of the Nominating and Governance Committee, and member of the Compensation Committee; Equinix Inc. and serves as Chair of the Nominating and Governance Committee and member of the Compensation Committee; CIBC and is a member of the Management Resources and Compensation Committee; Procore and serves as Chair of the Compensation Committee and member of the Nominating and Governance Committee.
Nanci has served on several other public companies boards including Talend SA, Donnelley Financial Solutions, Tibco Software Inc., Deltek Inc, and Hyperion Solutions.
Nanci is co-founder of the Center for Conscientious Leadership committed to the development of the next generation of leaders, and is a Director Champion of the GOOD Directors Program.
Nanci is a graduate of Queen’s University, Kingston, Canada.
Executive Chair and CEO, Cerevel Therapeutics; Board Chair — Yumanity Therapeutics; Board Member — McKesson and Regeneron
Dr. Coles is executive chairman and chief executive officer of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Dr. Coles is a founding investor and the chairman of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases.
Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005.
Educated at Johns Hopkins University, earned a medical degree from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
Dr. Coles currently serves on the board of directors of McKesson Corporation and Regeneron (NASDAQ: REGN) and is a member of the board of trustees for Johns Hopkins University and Johns Hopkins Medicine. Dr. Coles is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; a member of the board of directors of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher; and a member on the Harvard Medical School Advisory Board.
Board Member — General Electric and MongoDB
Francisco (Frank) D’Souza co-founded Cognizant Technology Solutions, a global multinational corporation that provides IT services, including digital, technology, consulting, and operations services in 1994 and served as the company’s Chief Executive Officer from January 2007 through March 2019. In addition to his tenure as CEO, he served as President from 2007 to 2012 and held a variety of senior management positions, including Chief Operating Officer from 2003 to 2006. He was elected to Cognizant’s Board of Directors in January 2007 and served as Vice Chairman of the board from 2018 until 2020.
As CEO, Frank was responsible for promoting Cognizant’s values and client-first culture, ensuring the company’s sustainable growth and driving long-term shareholder value. From Cognizant’s IPO until the time he stepped down from the CEO role, Cognizant stock returned almost 29,000%. During his 12 years as CEO, he oversaw a period of sustained growth, transformation, innovation and success, including:
- a 10x increase in revenue, from $1.4 billion in 2006 to $16.1 billion in 2018;
- a 7x increase in headcount, from 39,000 in 2006 to 282,000 in 2018;
- Cognizant joining the Fortune 200 and being named one of Fortune magazine’s “World’s Most Admired Companies” for 11 years in a row.
Frank is currently a director of General Electric, where he is a member of the Audit Committee and Management Development & Compensation Committees. He also serves on the Board of MongoDB, a software company that offers a modern general purpose database platform where he’s chair of of the Compensation and a member of the Nominating & Governance Committees.
In addition to corporate boards, Frank serves on the Board of Trustees of Carnegie Mellon University and the New York Hall of Science. He is a Fellow of the World Economic Forum and served as the 2019 Chairman of the IT and Electronics Governors community at the Forum. Fortune magazine named Francisco a “Fortune Businessperson of the Year” for 2015 and 2017, highlighting his mission to prioritize services that help clients adapt and keep pace with the digital revolution.
Frank was born in Nairobi, Kenya, and has traveled widely and lived in countries ranging from Panama to Hong Kong where he obtained his Bachelor's degree from the University of Macau. He also received an M.B.A. from Carnegie-Mellon University.
Board Chair — Numenta; Board Member — Stanford Health Care and Twilio
Donna is a serial entrepreneur best known for her work as CEO of Palm Computing and then Handspring, pioneers of the first successful handheld computers and smartphones. Previously, Donna spent 10 years in a multitude of sales, sales support, and logistics functions—both at Apple and at Claris, an Apple software subsidiary. She founded Numenta with her long-time business partner, Jeff Hawkins, in 2005.
Donna earned a B.A. from Yale University, and an M.B.A. from Harvard Business School. In addition to chairing Numenta’s board, she currently serves on the boards of Stanford Health Care (Palo Alto, CA), and Twilio (NYSE: TWLO). Donna also served on the board of Yale University from 2006-2018, including two years as Senior Fellow.
Board Member — PTC, Braze, and Collibra
Phil is a veteran Silicon Valley entrepreneur, with 40 years of experience building and leading breakout technology companies. He retired in 2016 from Marketo, where he served as Chairman and CEO since co-founding the company in 2006. Prior to founding Marketo, Phil served as president and COO of Epiphany, and earlier, as COO of Red Brick Systems.
Phil serves on the boards of PTC (Nasdaq: PTC), Braze, and Collibra, and advises a number of early stage companies and entrepreneurs. He is active writer and speaker on topics related to digital marketing, big data and analytics, subscription business models, and entrepreneurial innovation, and is the author of Revenue Disruption (Wiley).
Together with his husband Daniel, Phil has spent more than 30 years working for domestic partnership benefits and marriage equality, and is a vocal champion for diversity of all kinds in the board room.
Phil holds a bachelor’s degree in History from Stanford University.
Board Chair — Orchard Therapeutics, Idera Pharmaceuticals, and Pieris Pharmaceuticals; Board Member — Voyager Therapeutics and Fulcrum Therapeutics
Jim Geraghty is an industry leader with over 35 years of strategic and operational experience. He serves currently as chairman of the boards of Orchard Therapeutics, Idera Pharmaceuticals, and Pieris Pharmaceuticals, and as a member of the boards of directors of Voyager Therapeutics and Fulcrum Therapeutics, each a publicly traded company. Mr. Geraghty was earlier an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund, and senior vice president of Sanofi, a top 5 pharma company. Prior to that, he served in a wide range of senior management roles at Genzyme Corporation, a pioneering biotechnology company, including senior vice president of international development, president of Genzyme Europe, and CEO of Genzyme Transgenics. He has spoken widely at industry, investor, and patient events. He served earlier as chairman of the board of Juniper Pharmaceuticals and a director of bluebird bio. His nonprofit boards include Bio Ventures for Global Health (BVGH), and earlier the Joslin Diabetes Center. He holds a B.A. from Georgetown, an M.S. from the University of Pennsylvania, and a J.D. from the Yale Law School.
President and CEO, ANSYS; Board Member — ANSYS and Citrix Systems
Dr. Gopal has been serving as the Company’s president and CEO since January 2017. From August 2016 through December 2016, Dr. Gopal served as the Company’s president and chief operating officer. He was appointed as an independent member of the Company’s Board of Directors in 2011, and served in that capacity until his employment by the Company as of August 2016. From April 2013 until he joined the Company, Dr. Gopal was an operating partner at Silver Lake, including a secondment to serve as interim President and COO at Symantec Corporation. From 2011 until 2013, he was senior vice president at Hewlett Packard. Prior to that, Dr. Gopal was executive vice president at CA Technologies from 2006. From 2004 to 2006, he worked for Symantec Corporation, where he served as executive vice president and chief technology officer. Earlier, Dr. Gopal served as CEO and a member of the board of ReefEdge Networks, a company he co-founded in 2000. Before that, he worked at IBM from 1991 to 2000, initially at IBM Research, and later in IBM’s Software Group.
Board Member — Fidelity National Information Services, Partners Group Holding AG, Philip Morris International, Ping Identity Holding Corp., and Unisys
Ms. Hook served as President and Chief Executive Officer of Neustar, Inc. (NYSE: NSR) from October 2010 until July 2018 and as President and Chief Operating Officer from January 2008 until 2010. She joined the Neustar board in 2010 and continued to serve in that capacity until July 2019. Previously, Ms. Hook served as President and Chief Executive Officer of Sunrocket, Inc., held several executive-level posts at America Online, Inc., was a partner at Brera Capital Partners, a global private equity investment firm, managing director of Alpine Capital Group, LLC, an investment banking firm, held several executive positions at Time Warner, Inc., was legal advisor to the Chairman of the Federal Communications Commission, and was a senior attorney at Viacom International, Inc.
Ms. Hook serves on the boards of Fidelity National Information Services Inc. (NYSE: FIS), a global leader in banking and payment solutions, Partners Group Holding AG (SIX: PGHN), a global private markets investment manager, Philip Morris International (NYSE: PM), a leading international tobacco company, Ping Identity Holding Corp. (NYSE: PING), a global pioneer in intelligent identity for enterprise, and Unisys Corporation (NYSE: UIS), a global information technology company.
Ms. Hook has previously served as Senior Independent Director of RELX PLC (FTSE: RELX) and RELX NV, providers of information solutions, Covad Communications (NASDAQ: COVD), Time Warner Telecom (NASDAQ: TWTC), K-12 Inc. and National Geographic Ventures. She currently serves on the National Security Telecommunications Advisory Committee (NSTAC) to which she was appointed in 2012 by President Obama. In this role, she co-led the NSTAC Report to the President on Big Data Analytics. In recognition of her personal and professional achievements, The Dickinson School of Law and Penn State University honored Ms. Hook as a 2012 Penn State Alumni Fellow.
Board Member — Gilead Sciences, Moderna, and Olema Oncology
Sandra J. Horning, M.D., FACP, FASCO, was Executive Vice President, Chief Medical Officer and Head of Global Product Development for Roche/Genentech from January 2014–October 2019 and, earlier, was Senior Vice President, Global Head of Oncology Clinical Science from September 2009-December 2013.
Dr. Horning currently serves on the Board of Directors of Gilead Sciences, Moderna and Olema Oncology, and she is a co-founder and Board Member of EQRx.
During her tenure at Genentech/Roche, she oversaw the successful development of 15 new molecular entities (NMEs) with 3 additional NMEs filed in 2019, numerous line extensions of marketed products, and 28 FDA Breakthrough Designations in oncology, hematology, neuroscience, ophthalmology, immunology and infectious disease.
In addition to leading the ~5000 person Global Product Development organization and chairing the Late Stage Portfolio Committee, Dr. Horning participated in broad collaborative efforts to accelerate innovative drug development including Breakthrough Designation and complete pathologic response and minimal residual disease as surrogate endpoints.
Dr. Horning served on the Board of Directors of Foundation Medicine from 2015-18. She was recognized as the 2020-1 Healthcare Business Women’s Woman of the Year, a 2018 San Francisco Business Times Women Who Lead in Life Sciences, a 2014 Fierce Biotech Top Woman, and the recipient of the 2017 University of California San Diego Excellence in Translational Medicine award.
Prior to joining Roche/GNE, Dr. Horning was a tenured professor, practicing oncologist and investigator, and held multiple leadership positions including University Fellow and Vice-Chair of the Department of Medicine at Stanford University, where she is an Emerita Professor of Medicine (Oncology and Blood and Bone Marrow Transplantation).
Sandra has authored more than 300 peer-reviewed journal articles, book chapters, reviews and editorials, and has served on the editorial boards of multiple peer-reviewed medical journals. She was named a Best Doctor in America consecutively from 1992-2008, served as a member of FDA’s Oncology Drugs Advisory Committee, Chairman of the Eastern Cooperative Oncology Group lymphoma committee and 2005-6 President of the American Society of Clinical Oncology.
Sandra received Bachelor of Arts and Doctor of Medicine degrees at the University of Iowa and completed post-doctoral training in internal medicine at the University of Rochester and in medical oncology at Stanford University.
President and CEO of Grameen America; Board Member — Apple, Unilever, Rockefeller Capital Management, and Wayfair
Andrea Jung is President and Chief Executive Officer of Grameen America, the fastest-growing microfinance organization in the United States. The former Chairman and Chief Executive Officer of Avon Products, Inc., and longtime champion of women’s issues, Ms. Jung was appointed by Grameen’s Founder and Chairman and Nobel Peace Prize Laureate Muhammad Yunus to the position in April 2014. Founded in 2008, Grameen America is dedicated to helping women who live in poverty build small businesses to create better lives for their families. Since Grameen America's inception, the organization has invested over $1.7 billion to more than 133,000 low-income women through its unique social capital model.
Ms. Jung, the longest-serving female chief executive in the Fortune 500, is respected as a trailblazer for women. She served as CEO of Avon from 1999 through April 2012, and as Chairman from 2001 through December 2012. As Avon’s first woman CEO and Chairman, Ms. Jung was also the first woman to serve as Chairman of the Cosmetic, Toiletry & Fragrance Association, and as Chairman of the World Federation of Direct Selling Associations.
During her tenure at Avon, she was responsible for developing and expanding economic earnings opportunities for over six million women in more than 100 countries. She has been lauded globally for her pursuit of public-private partnerships to end violence against women and to stem the breast cancer epidemic. Under her leadership, the Avon Foundation for Women raised and awarded nearly $1 billion to support health and empowerment causes, becoming the largest women-focused corporate philanthropy around the world. Ms. Jung's efforts were recognized by the Clinton Global Initiative, which in 2010 honored her with the Clinton Global Citizen Award for her visionary leadership in solving pressing global challenges.
Throughout her corporate tenure, Ms. Jung ranked consistently among the top leaders on lists including Fortune’s “Most Powerful Women in Business,” Forbes’ “Most Powerful Women in the World,” and the Financial Times’ “Top Women in World Business.”
Ms. Jung is a graduate of Princeton University. She is a member of the Board of Directors of Apple Inc., Unilever, Rockefeller Capital Management, and Wayfair Inc. She previously served on the boards of General Electric and Daimler AG.
Board Chair — AT&T; Board Member — Ford Motor Company and MetLife
Bill served as the United States Ambassador to the European Union from December 2009 to August 2013, appointed by President Barack Obama. As Ambassador, he worked actively to promote transatlantic trade and investment and to eliminate regulatory barriers to commerce. For his contributions, the American Chamber of Commerce to the European Union awarded Ambassador Kennard the Transatlantic Business Award, the organization’s highest honor.
Before serving as an Ambassador, Bill was a Managing Director at The Carlyle Group, a global asset management firm, where he led private equity investments in the telecommunications and media sectors. Before joining The Carlyle Group, Bill served as chairman of the US Federal Communications Commission (“FCC”), appointed by President Bill Clinton. Before his appointment as Chairman, he served as the FCC’s General Counsel. During his tenure at the FCC, he shaped policies that created an explosion of new wireless phones, brought the Internet to a majority of American households and incentivized billions of dollars of investment in new broadband technologies. At the same time, he implemented bold new policies to bridge the digital divide in the United States and around the world.
U.S. News and World Report dubbed Chairman Kennard “a consumer champion for the digital age.” He has received many honors and awards for his accomplishments including honorary degrees from Howard University, Gallaudet University and Long Island University, and awards from the Congressional Black Caucus Foundation, the Easter Seals Foundation and the Hispanic Chamber of Commerce.
Upon returning to the United States from Brussels in 2013, Bill resumed his career in the private sector. He co-founded and serves as Chairman of Velocitas Partners LLC, an asset management firm. He also serves as an advisor to and founding investor in Staple Street Capital and Astra Capital Management, both private equity firms. He is the Chairman of the Board of directors of AT&T, Inc. He also serves on the boards of directors of Ford Motor Company and MetLife, Inc. Previously he served as a director of several other public companies including Duke Energy Corporation, Sprint Corporation, The New York Times Company and Dex Media, Inc., as well as a number of private companies controlled by The Carlyle Group.
Bill has also served on several nonprofit boards including the Yale University Council, Gallaudet University, the Joint Center for Political and Economic Studies, and One Economy Corporation. He currently serves as a trustee of Yale University and Eagle Hill School and is a member of the board of directors of the International African American Museum.
Bill graduated from Stanford University. He received his law degree from Yale Law School in 1981, where he met his wife, Deborah Kennedy (YLS ’79). They have one son, Robert. Bill and Deborah divide their time between Washington, DC and Charleston, SC.
Board Member — American Electric Power, Nationwide, and Service Corporation International
Sara Martinez Tucker currently serves on the Boards of Directors of American Electric Power, Nationwide and Service Corporation International. She previously served on the Sprint and Xerox boards of directors. Tucker is on the University of Notre Dame’s Board of Trustees and was the former chairman of the University of Texas System Board of Regents. She previously served as CEO of the National Math + Science Initiative, an organization focused on improving student performance in science, technology, engineering and math (STEM).
Prior to that, she served as the under secretary at the U.S. Department of Education. She was nominated to that post, the nation's top higher education official, by President George W. Bush on September 5, 2006, and confirmed by the Senate on December 9, 2006. As under secretary, she oversaw all policies, programs and activities related to postsecondary education, vocational and adult education, and federal student aid.
Tucker’s personal accomplishments included the development and implementation of two signature programs to increase access to college: a joint initiative with the U.S. Treasury Department to make nearly $70 billion in 2008-09 federal student loans available during the nation’s financial crisis, an effort described by the Wall Street Journal as “one bright spot in a season of crises and bailouts,” and an innovative new website, college.gov, which helps students and families prepare for college. College.gov received Computerworld’s Laureate Medal for exceptional use of technology to better society.
In addition to the successful oversight of over $32 billion in disbursed appropriations and almost 5,600 discretionary awards, Tucker provided expert testimony before Congressional committees and special hearings, led policy discussions within the Administration and with trade associations, and led or represented the United States in international delegations.
Prior to joining the Department, Tucker worked for nine years as the CEO and president of the Hispanic Scholarship Fund (HSF), where she pursued an aggressive goal to double the rate of Hispanics earning college degrees. In her time at the helm of HSF, Tucker raised $280 million for scholarships, growing annual scholarships from $3 million to over $25 million, and to launch community outreach programs to raise college expectations in Latino families and communities.
Prior to joining HSF in 1997, Tucker spent 16 years at AT&T, becoming the first Latina to reach the company's executive level. In her last assignment at the company, she served as a regional vice president for AT&T's Global Business Communications Systems, where she led a $400 million division to its highest profit levels. She also served as vice president for Consumer Operations, a $370 million operation with 6,500 employees serving AT&T's 80 million consumers. Under her leadership, this group contributed to the division's receipt of the Malcolm Baldrige Quality Award.
Born and raised in Laredo, Texas, she earned her bachelor's degree with honors in journalism at the University of Texas at Austin. She worked for two years as a reporter for the San Antonio Express before returning to the University of Texas to earn her master's in business administration with high honors.
Among her many awards and honors, in 2005, Time magazine named her one of the 25 most influential Hispanics in the United States. Tucker has been named as an Outstanding Young Texas Ex and a Distinguished Alumna at The University of Texas at Austin and has received honorary doctorates from the University of Notre Dame, Boston College and the University of Maryland University College.
She and her husband, Greg, a management consultant, live in Dallas.
Board Member — Levi Strauss & Co., Poshmark, Affirm, and advisory board of Gorilla Commerce
Jenny Ming is a seasoned retail and consumer product CEO with extensive board experience. She served as President and CEO of Charlotte Russe, a fast fashion/specialty brand from 2009-2019. Prior to Charlotte Russe, Ms. Ming was one of the founding members of the Old Navy executive team that conceived and launched this innovative retail concept and the first ever value specialty brand targeting the modern family in 1994. She became Old Navy's first President from 1999 to 2006. Ms. Ming is currently on the board of Levi Strauss & Co., Poshmark, Affirm, and advisory board of Gorilla Commerce. Previously she has also served on the board of Kaiser Foundation Health Plans and Hospitals, Barneys New York and Paper Source. Ms. Ming has been recognized by Fortune, Business Week, WallStreet Journal and the New York Times for outstanding leadership in business.
Executive Vice President of Strategy, ModeX Therapeutics; Board Member — Medtronic, Moderna, and Lyell
Betsy Nabel is Executive Vice President of Strategy at ModeX Therapeutics, a biotech company focused on immunotherapies for cancer and viral diseases. She previously served as President of Brigham Health, consisting of hospitals and physician organizations operating inpatient and outpatient facilities, clinics, primary care health centers, diagnostic and treatment facilities, research laboratories, and postgraduate medical and scientific education and training programs, as well as Harvard Medical School’s major teaching affiliate from 2010 to March 1, 2021. During that period, she also served as a Professor of Medicine at Harvard Medical School.
A cardiologist and distinguished biomedical researcher, Nabel’s diverse experience as an executive, physician, research scientist, and health care policy advocate have molded her vision for the future of medicine. At Brigham Health, Nabel lead an organizational transformation focused on innovation and building a collaborative culture to reshape healthcare delivery, compassionate care, scientific discovery, and training the next generation of medical and scientific leaders. Her focus on global expansion of Brigham Health, research commercialization and philanthropy doubled annual operating revenues to $5B and raised more than $1.75B in philanthropic contributions.
Nabel’s advocacy and health policy work is driven by her believe that care must be patient centered and access to high-quality healthcare is a basic human right. As director of the NIH’s National Heart, Lung, and Blood Institute from 2005-2009, Nabel leveraged a $3B research portfolio to establish pioneering scientific programs in genomics, stem cells, and translational research; to lead health care policy work on global health in cardiovascular and other chronic diseases; to engage with Department of Health and Human Services leadership on value based healthcare. One of her signature advocacy efforts was the development the Heart Truth campaign featuring the now iconic red dress, which resulted in raised heart health awareness in women through unprecedented industry partnerships.
Nabel has been named one of the nation’s top leaders in medicine by Modern Healthcare and Becker’s Hospital Review, and one of Boston’s 50 most powerful people by Boston magazine. Her numerous honors include the Distinguished Bostonian Award from the Greater Boston Chamber of Commerce, the George M. Kober Medal from the Association of American Physicians, the Champion in Health Care award from the Boston Business Journal, the Willem Einthoven Award from Leiden University in the Netherlands, the Amgen-Scientific Achievement Award, the Rambam Award from Rambam Health Care Campus in Israel, two Distinguished Achievement Awards and the Eugene Braunwald Academic Mentorship Award from the American Heart Association, and nine honorary doctorates.
Betsy serves on the boards of Medtronic, Moderna, Lyell, and the Lasker Foundation. Together with Drs. Gary Nabel and Elias Zerhouni, Betsy recently founded ModeX Therapeutics, focused on innovative immune therapies targeting cancer and infectious diseases.
Building on her lifelong commitment to improving health through science, in 2015 Nabel became the first ever chief health and medical advisor to the National Football League. In this newly created advisory role, Nabel provided strategic input to the NFL’s medical, health and scientific efforts and identified areas for the NFL to enhance player safety, care and treatment. She guided the NFL to hire its first full-time Chief Medical Officer.
Her colleagues have elected her to the American Academy of the Arts & Sciences, the National Academy of Medicine, the Association of American Physicians, the American Society for Clinical Investigation, and she is a Fellow of the American Association for the Advancement of Science.
An accomplished physician-scientist, Nabel’s work on the molecular genetics of cardiovascular diseases produced 17 patents and more than 250 scientific publications. Nabel’s scientific contributions in cardiovascular gene transfer have developed molecular and cellular techniques to treat heart disease, leading to establishing two start-up companies.
A native of St. Paul, Minnesota, Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Women’s Hospital and Harvard University. After training, Nabel was chief of the Division of Cardiology, director of the Cardiovascular Research Center, and Professor of Internal Medicine and Physiology at the University of Michigan from 1987-1999. She joined the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health as Scientific Director of Clinical Research in 1999, and then served as Director of the NHLBI from 2005-2010. Betsy and her husband Gary have three children, all of whom have careers in medicine as physician-scientists.
Board Member — American Well Corp., Cerevel Therapeutics, Global Blood Therapeutics, and Twilio
Originally from the South Side of Chicago, Patrick was awarded a scholarship at 14 to Milton Academy through the Boston-based organization A Better Chance.
After Harvard College and Harvard Law School, he clerked for a federal appellate judge and then launched a career as an attorney and business executive, becoming a staff attorney at the NAACP Legal Defense Fund, Assistant Attorney General for Civil Rights in the Clinton administration, a partner at two Boston law firms and a senior executive at two Fortune 50 companies.
In 2006, in his first bid for elective office, he became Massachusetts’ first African-American governor.
During his eight year tenure, Patrick helped revive a battered economy through the expansion of affordable health care, unprecedented investments in Massachusetts public schools and public infrastructure, and initiatives stimulating clean energy and biotechnology. Under his leadership, Massachusetts extended health care to over 98 percent of its residents, won a national Race to the Top educational grant, steered the state to a 25-year high in employment, and ranked first in the nation in student achievement, energy efficiency, veterans services, and entrepreneurship.
From April 2015 to December 2019, he founded and built an impact investment fund at Bain Capital, where he focused on investments that deliver both a competitive financial return and significant positive social impact. He continues to invest in stakeholder models of mission driven business as a Senior Advisor to Bain Capital and a board member.
He is the Founder & Chairman of TogetherFUND, a political action committee to support progressive politics and grassroots groups working to drive turnout and engagement among disenfranchised and marginalized voters. He continues this work as co-chair of American Bridge 21st Century through its Bridge Together initiative.
Patrick is a Rockefeller Fellow, a Crown Fellow of the Aspen Institute, and the author of two books, A Reason to Believe: Lessons from an Improbable Life and Faith in the Dream: A Call to the Nation to Reclaim American Values. He lives in Western Massachusetts with his wife Diane, his dogs and his bees.
Operating Partner, General Atlantic; Founder and Chairman, Life Science Cares; Board Member — Vir Bio, PathAI, Immunocore, and Third Harmonic Bio
Rob Perez is a biopharmaceutical operating executive with more than 30 years of experience in the industry. He is currently serving as an Operating Partner at General Atlantic, a global growth equity firm, providing strategic support and advice to the firm’s life sciences investment team and portfolio companies. Rob is also a member of the Board of Directors at Vir Bio, PathAI, Immunocore, and Third Harmonic Bio.
Rob is the Founder and Chairman of Life Science Cares, an organization that provides human and financial capital from the life sciences industry to the best non-profits working to alleviate the impact of poverty in the US. Life Science Cares now operates in Boston, San Diego, Philadelphia and the San Francisco Bay Area.
Additionally, Rob is the co-founder of Biopharma Leaders of Color (BLOC), a community of leaders united to advance the success and access of under-represented people of color throughout the life sciences industry.
Rob also serves on the Board of Trustees of The Dana Farber Cancer Institute.
In 2022, Rob was selected by STAT News as one of 46 inaugural members of its’ STATUS List, which was described as “the most definitive and consequential accounting of leaders in health, medicine and science”.
Previously, Rob was the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, when the company was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection). He also served as Executive Vice President and Chief Operating Officer, and President prior to becoming CEO.
Before joining Cubist, he served as Vice President of Biogen, Inc.’s US CNS business unit, where he was responsible for commercial leadership of an $800 million business. He joined Biogen in 1995, and was one of the architects of the commercial model that launched the company’s first commercial product, AVONEX®.
Rob earned a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
Board Member — Moderna and VMware
Paul Sagan is senior advisor and executive-in-residence (XIR) at General Catalyst. He is a director of Moderna and VMware, and previously served as a director of Akamai, Digitas, Dow Jones, EMC and iRobot.
Board Member — MasterCard, Eli Lilly, Brixmor Property Group, and Cerevel Therapeutics
Gabrielle Sulzberger is a seasoned financial executive with over 30 years of experience assisting public and privately held companies in consumer products, retail, financial services and life sciences. Gabrielle has helped companies globally navigate disruption and transformation, execution of major M&A transactions, and engagement with shareholder activists. She brings deep corporate governance experience through her work with corporate boards and is qualified to serve on audit committees as a financial expert.
Ms. Sulzberger currently serves as a strategic advisor to TwoSigma Impact, a New York based private equity fund. Previously, Ms. Sulzberger was a General Partner of Fontis Partners, a private equity fund based in Pasadena, California. Prior to joining Fontis Partners, Gabrielle served as CFO of several public and private companies, including Gluecode Software, a venture-backed open source software company which was sold to IBM, and Crown Services, a California based consolidation of commercial contractors.
Until August of 2017, Ms. Sulzberger served as Chairman of the board of Whole Foods, where for 13 years she had previously served as Chair of the company’s audit committee. She currently serves on the board of MasterCard, Eli Lilly, Brixmor Property Group, where she chairs the governance committee, and Cerevel Therapeutics, where she chairs the Audit Committee. She also serves on several private company boards: Acorns, JustWorks, and True Food Kitchen, where she is Chairman of the Board. Previously Ms. Sulzberger served on four other public company boards: Teva Pharmaceuticals, Stage Stores, IndyMac Bank, and Bright Horizons, and numerous private company
Gabrielle is a Trustee of the Ford Foundation, and is chair of the governance and mission related investments committees. She also serves on the Boards of the Metropolitan Museum of Art, Sesame Street Workshop, TimesUp and Trinity Church Wall Street. She is a Henry Crown Fellow of the Aspen Institute.
Ms. Sulzberger received her B.A. from the Woodrow Wilson School of Princeton University. She received her M.B.A. from Harvard Business School and J.D. from Harvard Law School and is a member of the Massachusetts Bar.
Board Chair — Dynatrace; Board Member — Hubspot
Jill Ward is a board member, business leader, and operating executive experienced in scaling products and companies in technology and business services. She currently serves as chair of the board of directors at Dynatrace Inc, and is a member of the board of directors at Hubspot, Inc. Previously, she served on the boards of directors of technology companies Carbon Black Inc, and Adaptive Insights Inc.
As an operating executive, Jill served as President and Chief Operating Officer of software and internet-of-things (IoT) provider Fleetmatics Group PLC. Prior to that, she was Senior Vice President and General Manager at software company Intuit. Earlier, she held leadership positions with a private equity funded customer contact outsourcing company, as well as with financial services firm Fidelity Investments and strategy consulting firm Bain & Company.
Jill holds a B.A. from Wellesley College and an M.B.A. from the Tuck School at Dartmouth College.
Board Member — Alphabet, Honeywell International, and Salesforce.com
Robin L. Washington is currently a member of the Board of Directors of Alphabet, Inc., Honeywell International, Inc., and Salesforce.com. She currently serves as chair of the leadership development and compensation committee for Alphabet and chair of the audit committee for Salesforce.com.. She is also a member of the Presidents Council & Ross Business School Advisory Board, University of Michigan; the UCSF Benioff Children’s Hospital Oakland Board of Directors; and a trustee of the Financial Accounting Foundation.
Ms. Washington served as Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc., from May 2008 – November 2019 where she oversaw Global Finance, Facilities and Operations, Investor Relations and the Information Technology organizations. Prior to Gilead, Ms. Washington was the Chief Financial Officer of Hyperion Solutions Inc. from 2006 – 2007, an enterprise software company that was acquired by Oracle Corporation in 2007. Prior to that, she spent nearly 10 years at PeopleSoft., where she served in a number of executive finance positions.
Ms. Washington is a certified public accountant and holds a bachelor’s degree in business administration from the University of Michigan and an M.B.A. from Pepperdine University.
Who will be the faculty for the program?
The faculty will be led by the co-leaders of Goodwin’s Annual Directors Forum, Stuart M. Cable and Lisa R. Haddad. In addition, the faculty for the program will include other Goodwin experts and selected guest faculty, including representatives from the ALLIES and the CHAMPIONS.
Stuart M. CablePartnerVice Chairman, Goodwin; Global Chair of M&A
Lisa R. HaddadPartnerCo-Chair, Public M&A / Corporate Governance
Deborah S. BirnbachPartnerCo-Chair, Complex Litigation & Dispute Resolution
Brackett B. DennistonSenior Counsel
Joshua M. ZachariahPartnerCo-Chair, Technology M&A